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Pharmacokinetics of FK 506 in Transplant Patients 
R. Venkataramanan, A. Jain, V.S. Warty, K. Abu-Elmagd, M. Aless.iani, J. Lever, A. Krajak, J. Flowers, 
S. Mehta. S. Zuckerman. J. Fung, S. Todo, and T.E. Starzl 
FK S06 has been in clinical use at the University of Pittsburgh Medical center since March 1989. Cur-
rently. it is used as the primary immunosuppressant in 
liver. kidney, and heart transplant patients. Use ofFK S06 
has resulted in a significant reduction in the dose of steroid 
used and is associated with a lower incidence of hyperten-
sion in transplant patients. At the present time there are 
nearly 1,600 patients receiving FK 506 therapy at this 
institution. Various pharmacokinetic aspects and factors 
affecting the pharmacokinetics of FK S06 in transplant 
patients will be discussed here. 
DOSAGE FORMS OF FK 506 
FK S06 is available for clinical use as an IV formulation. 
Since the aqueous solubility of FK 506 is less than 100 
ng/mL. the IV formulation contains a non ionic surfactant 
to solubilize FK 506 in aqueous medium. The IV formula-
tion must be diluted with S% dextrose or normal saline and 
administered as an infusion to patients. FK 506 in 5% 
dextrose for ir\iection is most stable and completely avail-
able from poly olefin bags or glass containers. I FK 506 
solution in normal saline is also completely stable and 
available from poly olefin bags or plastic syringes. 
Initially, FK 506 was administered at a dose of 0.15 
mg/kg/d, as an IV infusion over 2 to 4 hours. twice a day. 
To minimize the potential side effects related to high peak 
concentrations of FK 506 at the end of a 2- or 4-hour 
infusion. it is administered as a continuous infusion over 24 
hours at the present time. The current practice is to 
administer a dose of 0.1 mg/kg/d as a continuous infusion 
over 24 hours. until the patient is able to tolerate oral 
intake. Patients normally receive an oral dose of 0.3 mg/kg 
(as a solid dispersion ofFK S06 in hard gelatin capsule) and 
further dosing adjustments are made based on the clinical 
status of the patient. the functional status of the liver and 
kidney. and the trough plasma FK 506 concentrations. 
ANALYTICAL METHODS 
The therapeutic plasma concentration of FK 506 appears 
to be approximately O.S to 2 ng/mL. At such low concen-
trations, FK 506 cannot be measured by high pressure 
liquid chromatography (HPLC) with ultraviolet (UV) de-
tection. Attempts to derivatize FK 506 to increase the 
detection limits have not been very successful. FK S06 
blood and plasma concentrations are currently measured 
by enzyme-linked immunoassay (ELISA) ,2 which involves 
minor modifications of the assay method published by 
Tamura et al. 3 While the ELISA assay is specific enough 
not to cross-react with several other drugs coadministered 
to transplant patients. it appears to cross-react with some 
of the metabolites of FK 506. The relative concentrations 
of these metabolites in blood or plasma and the extent of 
cross-reactivity of these metabolites with FK 506 mono-
clonal antibody have not been completely characterized. 
PHARMACOKINETIC STUDIES 
Pharmacokinetic studies have been carried out after short 
IV infusion (2 to 4 hours). continuous IV infusion. or oral 
administration of FK 506. Multiple blood samples were 
collected over a 12- or 24-hour dosing interval. Blood 
samples were incubated at 37°C for 30 minutes to I hour 
and centrifuged at 37°C. Plasma samples were immediately 
frozen at -70°C. until analyzed for FK S06 by ELISA. In 
certain studies whole blood samples kept frozen at -70°C 
were also assayed by a modified procedure.2 In three 
patients receiving twice a week FK 506 dosing, blood 
samples were collected for up to 72 hours after IV infusion 
ofFK 506. 
Following IV infusion. peak plasma concentrations are 
reached at the end of infusion. The drug concentration 
declines rapidly immediately after the end of infusion 
indicating rapid distribution of the drug outside the plasma 
compartment. Once distribution equilibrium is reached. 
FK 506 concentrations decline at a slower rate correspond-
ing to the disposition of the drug (Fig 1).4-6 The behavior of 
the drug can be adequately described by a two compart-
ment model in most of the patients. The half life of FK 506 
based on plasma concentrations ranges from 3.5 to 40.5 
hours. while the clearance ranges from 7 to 103 mUminlkg 
(Table I). In three patients who were studied for 72 hours. 
the half lives were 22. 34. and 36 hours. The volume of 
distribution at steady state ranges from 5.6 to 65 Llkg. 
These observations indicate a large interindividual vari-
ability in the pharmacokinetics of FK 506 in transplant 
patients. 
Following oral administration. the drug is absorbed very 
rapidly in certain patients with peak plasma concentrations 
being reached within 0.5 hours after oral dose. while in 
other patients the drug appears to be absorbed continu-
ously over a prolonged time period yielding essentially a 
flat oral absorption profile (Fig 2). 5 While the reasons for 
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Fig 1. Plasma concentration time curve after IV administration of 
0.15 mg/kg of FK 506 to one patient. 
such an observation are not completely understood. poor 
dissolution of FK 506 in gastric fluids due to low aqueous 
solubility and alterations in gastric motility in transplant 
patients are likely to be partially responsible for this 
observation. The oral bioavailability of FK 506 ranges 
from 5% to 67%, with a mean value of approximately 27%. 
FK 506 appears to be absorbed well from the transplanted 
small bowel. Small bowel transplant patients require FK 
506 oral maintenance doses similar to that used in liver 
transplant patients in order to maintain adequate immuno-
suppression. Adequate absorption of FK 506 by the trans-
planted gut has made small bowel transplantation more 
feasible with the use of oral FK 506 treatment. 
In blood, FK 506 is primarily associated with red blood 
cells (RBCs). Intracellular contents appear to be responsi-
ble for the extensive binding of FK 506 to RBCs (unpub-
lished observations). It is possible that RBCs may contain 
large amounts of FK binding protein (FKBP). The blood to 
plasma ratio of FK 506 in normal subjects at a total FK 506 
concentration of to ng/mL is 12. The trough blood to 
plasma concentration ratio of FK 506 in transplant patients 
ranges from 3.6 to 39 with a mean of 10. In plasma. FK 506 
is primarily associated with at acid glycoprotein (unpub-
lished observations). This is in contrast to cyclosporine 
(CyA), which is primarily associated with lipoproteins in 
plasma.7 Outside the vascular system. FK 506 appears to 
be distributed in the heart, lung, spleen. kidney, and 
pancreas.4 No FK 506 can be detected in the cerebrospinal 
Table 1. Pharmacokinetics of FK 506 
Paramel8lS' 
TIme to peak concentrations (ng/mL) 
Extent of absorption (%) 
Half life (h) 
Total body clearance (mUminlg) 
Renal clearance (mUmin) 
Volume of distribution (Ukg) 
0.5-4 h 
5-67 (mean 27) 
3.5-40.5 
7-103 (mean about 30) 
<1 
5-65 Ukg 
'Based on plasma concentrations analyzed by solid phase extraction and 
EUSA. 
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Fig 2, Plasma concentration time curve after oral administration 
of 0.3 mg/kg to three different patients. 
fluid of patients with neurotoxicity. suspected to be related 
to FK 506 therapy. The concentration of FK 506 in 
placental tissue is greater than that in plasma indicating the 
potential transfer of FK 506 to the fetus (unpublished 
observations) . 
FK 506 is primarily eliminated by metabolism.4 •6 Most 
of the metabolites are excreted in the bile. We have 
isolated several metabolites of FK 506 from bile samples 
obtained from rats and humans. FK 506 metabolites have 
also been generated by incubation of FK 506 with rat liver 
microsomes (unpublished observations). FK 506 appears 
to undergo monodemerhylation. didemethylation, hydrox-
ylation, and a combination of monodemethylation and 
hydroxylation. These metabolites are similar to the FK 506 
metabolites isolated from human small bowel and liver 
microsomes.8 In addition. there is preliminary evidence to 
suggest the presence of conjugates of FK 506 and its 
metabolites in human bile. However. less than 5% of the 
dose is excreted in the bile as FK 506 or its conjugates. 
Less than I % of the I V dose is excreted in the urine as 
unchanged FK 506. Small amounts of FK 506 conjugates 
are also excreted in the Uline. 
FACTORS AFFECTING FK 506 
PLASMA CONCENTRATIONS 
Several factors contribute to the observed inter and intra-
individual variability in FK 506 plasma concentrations in 
transplant patients. These include factors that alter the 
absorption, distribution. and elimination of FK 506. 
Studies in dogs indicate that the absorption of FK 506 is 
significantly increased in experimentally induced cholesta-
sis, presumably due to decreased presystemic metabo-
lism.9 In addition. biliary diversion or addition of exoge-
nous bile salts in the presence or absence of endogenous 
bile did not significantly alter the extent of FK 506 absorp-
tion.9 These observations indicate that in contrast to Cy A. 
the absorption of FK 506 is less dependent on the avail-
ability of bile. From a practical point of view, there is no 
need to decrease the dose of FK 506 when the t-tube is 
'. 
! 
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Fig 3. Relationship between dose (mg/kg/d) and steady state 
plasma concentration (ng/mL) of FK 506 as measured by ELISA in 
clinically stable liver and kidney transplant patients. 
clamped in liver transplant patients. 5. iO Preliminary stud-
ies indicate that food does not alter the extent of absorp-
tion of FK 506 in liver transplant patients. In vitro studies 
indicate a significant loss of FK 506 from simulated gastric 
fluid in the presence of magnesium oxide and aluminum 
hydroxide gel. Until further in vivo data become available 
it is prudent to dose FK 506 and antacids separately.il The 
distribution of FK 506 within blood is influenced by 
hematocrit, FK 506 concentrations, temperature of the 
blood sample, and the concentration of plasma proteins. 
Changes in one or more of these factors may contribute to 
the variability in the relative distribution of FK 506 in 
blood from transplant patients. It is well known that 
hematocrit increases with time after renal transplantation 
and that al acid glycoprotein concentrations are signifi-
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cantly increased in transplant patients when compared 
with normal subjects. 12 
FK 506 is primarily eliminated by metabolism. Several 
factors known to alter drug metabolism also alter the 
elimination of FK 506. Following IV administration of 0.15 
mg/kg/d. 24-hour trough plasma FK 506 concentrations are 
normally higher in patients with liver dysfunction when 
compared with patients with normal liver function. IO•13 
Correspondingly, patients with liver dysfunction tend to 
have longer half-lives and smaller clearance values. 10 With 
an improvement in liver function the half-life decreases to 
normal values. Cold ischemia and reperfusion injury to the 
liver may also alter the clearance ofFK 506. Impairment in 
the elimination of FK 506 due to ischemic damage of the 
liver is expected to resolve with time. 
Increase in FK 506 concentrations is also seen when FK 
506 is coadministered with c1otrimazole, ketoconazole. 
erythromycin. fluconazole. diltiazam, and cimetidine in 
rats. Erythromycin. fluconazole. methylprednisolone. and 
c1otrimazole-mediated increases in FK 506 concentration 
have also been observed in transplant patients. In patients 
who simultaneously receive hepatic drug metabolizing 
enzyme inducers or inhibitors. FK 506 should be used with 
caution. Another drug interaction that is of some impor-
tance is the interaction between FK 506 and cyclosporine 
(CyA). Combined use of these two agents results in 
synergistic immunosuppressionl4 and increased nephro-
toxicity.is FK 506 inhibits CyA metabolism in vitro. 16 
However, in liver transplant patients, short-term treatment 
with FK 506 does not appear to alter Cy A clearance.17 
Studies in dogs indicate that while FK 506 does not alter 
CyA clearance, it may increase FK 506 oral bioavailabil-
ity, presumably due to inhibition of presystemic metabo-
Table 2. Comparison of Kinetics of FK 506 and CyA 
Absorption 
Rate 
Extent 
Bile 
Condition 
Small bowel 
Transplant 
Distribution 
Blood: plasma 
Depends on 
Major binding protein in plasma 
Metabolism 
Metabolism 
Pathways 
Excretion 
Parent drug 
Metabolites 
Activity 
Parent drug 
Metabolites 
Variable 
50/0-67% 
Less essential 
Good absorption 
>12; 4-39 
FK 506 
Hematocrit, temperature. drug concentration, 
plasma protein concentration 
",1 acid glycoprotein 
>980/0 
Hydroxylation, demethylation, conjugation 
<2% in urine 
Primarily in bile 
Most active 
A lot less active 
Variable 
<5-89% 
Very essential 
Poor absorption 
About 2 
CyA 
Hematocrit, temperature, drug concentra-
tion, plasma protein concentration 
Lipoprotein 
>98% 
Hydroxylation, demethylation, conjugation 
<2% in urine 
Primarily in bile 
Most active 
Less active 
, 
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Table 3. Dosing Recommendation for FK 508 
. Condition 
Switch from IV to oral therapy 
T·tube clamping 
FK506 
Threefold increase in dose 
No change In dose 
CyA 
Threefold increase in dose 
Decrease dose 
Pediatric patients About two times higher dose compared About two to three times higher dose com-
·with aduits pared with adults 
Liver dysfunction 
Renal dysfunction 
Decrease IV dose; decrease oral dose 
Does not affect kinetics 
Decrease IV dose; increase oral dose 
Does not affect kinetics 
Decrease dose to decrease levels if renal Decrease dose to decrease levels if renal dys-
Dialysis 
dysfunction is related to the drug 
Not removed by dialysis 
function is related to the drug 
Not removed by dialysis 
Decrease dose Decrease dose Inhibitors of hepatic metabolism 
Inducers of hepalic metabolism Monitor drug level: increase dose Monitor drug level; may need to increase dose 
!ism. 18 This interaction is similar to the reported interac-
tion between CyA and erythromycin in patients. 19 
Pediatric patients in general tolerate FK 506 better than 
adults. This may be related to the higher clearance of FK 
506 from pediatric patients when compared with adult 
transplant patients (unpublished observations I. Pediatric 
and adult patients appear to absorb FK 506 similarly. On 
an average, pediatric patients require nearly twice the FK 
506 dosage (mg/kg) given to adults in order to maintain 
similar therapeutic plasma concentrations. 20 
FK 506 is not dialyzable. This may be related to the 
extensive binding of FK 506 to blood proteins and the large 
volume of distribution of this drug. Dialysis will be of 
limited use in FK 506 overdosing. 
THERAPEUTIC MONITORING 
FK 506 doses of 2 to 24 mg/d are required in order to 
maintain therapeutic plasma trough concentrations in the 
range of 0.5 to 2 ng/mL in clinically stable liver and kidney 
transplant patients (Fig 3). This indicates that even in 
patients with normally functioning liver and kidney. there 
is wide variability in the kinetics of FK 506. In addition. it 
has been shown that nephrotoxicity is the principal side 
effect of FK 506. It is therefore essential to monitor the 
blood or plasma concentration of FK 506 in patients to 
minimize incidence of the rejection and toxicity. In adopt-
ing an analytical procedure for routine therapeutic moni-
toring, one should consider the specificity, sensitivity. 
rapid turnaround time. and the precision of the method 
used. While immunologic monitoring is the ideal method 
for optimal immunosuppression. current status of this 
technology does not permit routine use of this procedure. 
Bioassay as proposed recently is an attractive tool but its 
routine use is limited by the long time necessary for 
conducting this assay.21 Studies are also currently under-
way to determine the right choice of biologic matrix (blood 
or plasma) that should be used for FK 506 monitoring. 
based on the relationship between blood or plasma con-
centrations and toxicity or rejection episodes. 
DOSING REGIMEN DESIGN FOR FK 506 
Studies in renal transplant patients indicate that at a 
plasma FK 506 concentration of 0.8 ng/mL or greater. 
more than 90% of the lymphocytes are inhibited in an in 
vitro test system.22 Considering 0.8 ng/mL to be the 
desired steady state concentration. one can calculate the 
average and maximum infusion rate required based on 
average and maximum plasma clearance of FKi. 506 in 
transplant patients. The average and maximum infusion 
rate required will be 0.04 and 0.093 mg/kgld. respectively. 
The maximum infusion rate derived from this formula is 
close to the current infusion regimen (0.1 mg/kg/d) used at 
our institution. Based on an oral bioavailability of 27%. the 
mean and maximal oral dose required should be 0.15 and 
0.35 mg/kg/d. respectively. Further adjustment in dosing 
regimen should be made based on liver function, kidney 
function, use of other immunosuppressants. and other 
drugs known to interact with FK 506. Table 2 summarizes 
the dosing recommendation for FK 506 as compared with 
CyA. 
In summary, FK 506 is similar to Cy A in terPls of the 
extent of absorption and metabolism (Table 3). However, 
they differ in the requirement of bile for absorption and in 
their distribution within blood. Liver disease also appears 
to alter FK 506 kinetics differently as compared with CYA. 
Improved understanding of the pharmacokinetics. phar-
macodynamics. and various factors affecting the pharma-
cokinetics and pharmacodynamics of FK 506 using spe-
cific assay methods will help us to optimize therapy with 
this novel and potent immunosuppressant. 
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